About Enterprise Therapeutics
Enterprise Therapeutics is a company based in Brighton (United Kingdom) founded in 2014 by Martin Gosling was acquired by Roche in October 2020. Enterprise Therapeutics has raised $86.19 million across 7 funding rounds from investors including Roche, Cystic Fibrosis Foundation and IP Group. The company has 9 employees as of December 31, 2021. Enterprise Therapeutics offers products and services including ETD001. Enterprise Therapeutics operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, GEn1E, Ikaria and Pulmatrix, among others.
- Headquarter Brighton, United Kingdom
- Employees 9 as on 31 Dec, 2021
- Founders Martin Gosling
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Enterprise Therapeutics Ltd
- Date of Incorporation 02 May, 2014
- Jurisdiction BRIGHTON, ENGLAND
-
Annual Revenue
$1.69 M (USD)14as on Dec 31, 2021
-
Net Profit
-$5.76 M (USD)29as on Dec 31, 2021
-
EBITDA
-$7.37 M (USD)26as on Dec 31, 2021
-
Total Equity Funding
$86.19 M (USD)
in 7 rounds
-
Latest Funding Round
$33.02 M (USD), Series B
Jan 29, 2024
-
Investors
Roche
& 9 more
-
Employee Count
9
as on Dec 31, 2021
-
Acquired by
Roche
(Oct 07, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enterprise Therapeutics
Enterprise Therapeutics offers a comprehensive portfolio of products and services, including ETD001.
Inhaled blocker targeting cystic fibrosis symptoms to improve breathing.
People of Enterprise Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
7 people
Advisor Team
5 people
Head Team
3 people
Finance and Accounting
2 people
Unlock access to complete
Funding Insights of Enterprise Therapeutics
Enterprise Therapeutics has successfully raised a total of $86.19M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $33.02 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Enterprise Therapeutics
Enterprise Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Cystic Fibrosis Foundation and IP Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked |
Investor details for Enterprise Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enterprise Therapeutics
Investment portfolio details for Enterprise Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enterprise Therapeutics
Detailed financials for Enterprise Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enterprise Therapeutics Comparisons
Peer comparison for Enterprise Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enterprise Therapeutics
Enterprise Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, GEn1E, Ikaria and Pulmatrix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein biologics are developed for treating rare diseases.
|
|
| Locked | Locked | Locked |
Precision medicines for lung-related diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| Locked | Locked | Locked |
Therapies for respiratory-related cardiopulmonary disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of respiratory diseases
|
Detailed competitors of Enterprise Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enterprise Therapeutics
Complete news archive for Enterprise Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enterprise Therapeutics
Enterprise Therapeutics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Enterprise Therapeutics is headquartered in Brighton, United Kingdom. It is registered at Brighton, East Sussex, United Kingdom.
Enterprise Therapeutics is a funded company, having raised a total of $86.19M across 7 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Enterprise Therapeutics is 9.
Annual revenue of Enterprise Therapeutics is $1.69M as on Dec 31, 2021.
Enterprise Therapeutics was founded in 2014 and is based in Brighton, United Kingdom. Focus is placed on developing therapeutic solutions for respiratory diseases, including cystic fibrosis. Additional efforts are directed toward treatments for chronic obstructive pulmonary disease and severe asthma. Operations center on pharmaceutical research and development within the biotechnology sector, with activities conducted primarily in the UK.
Enterprise Therapeutics's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
Enterprise Therapeutics offers ETD001.
Enterprise Therapeutics has 10 investors. Key investors include Roche, Cystic Fibrosis Foundation, IP Group, Imperial Innovations, and Panakes Partners.